PL363245A1 - Compounds specific to adenosine a1 - Google Patents

Compounds specific to adenosine a1

Info

Publication number: PL363245A1
Authority: PL; Poland
Prior art keywords: adenosine; compounds specific; compounds; specific
Prior art date: 2000-12-01

Application number

PL01363245A

Other languages

Polish (pl)

Inventor

Arlindo L. Castelhano

Bryan Mckibben

David J. Witter

Original Assignee

Osi Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-01

Filing date

2001-11-30

Publication date

2004-11-15

2000-12-01 Priority claimed from US09/728,316 external-priority patent/US6680322B2/en

2000-12-01 Priority claimed from US09/728,616 external-priority patent/US7160890B2/en

2000-12-01 Priority claimed from US09/728,607 external-priority patent/US6664252B2/en

2001-11-30 Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.

2004-11-15 Publication of PL363245A1 publication Critical patent/PL363245A1/en

Links

OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
239000002126 C01EB10 - Adenosine Substances 0.000 title 1
229960005305 adenosine Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL01363245A 2000-12-01 2001-11-30 Compounds specific to adenosine a1 PL363245A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US09/728,316 US6680322B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A1 receptors and uses thereof
US09/728,616 US7160890B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A3 receptor and uses thereof
US09/728,607 US6664252B2 (en)	1999-12-02	2000-12-01	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (1)

Publication Number	Publication Date
PL363245A1 true PL363245A1 (en)	2004-11-15

Family

ID=27419112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01363245A PL363245A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1

Country Status (20)

Country	Link
EP (1)	EP1347980A4 (en)
JP (1)	JP4579497B2 (en)
CN (1)	CN1263757C (en)
AP (1)	AP1893A (en)
AU (1)	AU2002248151B2 (en)
BR (1)	BR0115847A (en)
CA (1)	CA2430577A1 (en)
CZ (1)	CZ20031831A3 (en)
EA (1)	EA007254B1 (en)
HU (1)	HUP0400692A3 (en)
IL (1)	IL155962A0 (en)
ME (1)	MEP35308A (en)
MX (1)	MXPA03004717A (en)
NO (1)	NO327207B1 (en)
NZ (1)	NZ525885A (en)
OA (1)	OA13295A (en)
PL (1)	PL363245A1 (en)
WO (1)	WO2002057267A1 (en)
YU (1)	YU42703A (en)
ZA (1)	ZA200303729B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5090531A (en) *	1990-01-10	1992-02-25	Lord Corporation	Electrophoretic fluid differential
JP4611524B2 (en)	1998-06-02	2011-01-12	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	Pyrrolo [2,3d] pyrimidine compositions and uses thereof
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (en) *	2001-10-04	2003-04-10	Merck Patent Gmbh	New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
DK1450811T3 (en)	2001-11-30	2010-02-15	Osi Pharm Inc	Compounds specific for adenosine A1 and A3 receptors and uses thereof
ATE466581T1 (en) *	2001-12-07	2010-05-15	Vertex Pharma	PYRIMIDINE-BASED COMPOUNDS AS GSK-3 INHIBITORS
US20030229067A1 (en)	2001-12-20	2003-12-11	Arlindo Castelhano	Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
CN1620294A (en)	2001-12-20	2005-05-25	Osi药物公司	Pyrimidine A2B selective antagonist compounds, their synthesis and application
WO2004041285A1 (en) *	2002-10-31	2004-05-21	Amgen Inc.	Antiinflammation agents
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (en)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
ES2344800T3 (en) *	2005-02-18	2010-09-07	Solvay Pharmaceuticals Gmbh	PHARMACEUTICAL COMPOSITIONS THAT INCLUDE NEP INHIBITORS, INHIBITORS OF THE ENDOGELINE AND DIURETIC ENDOTELINE PRODUCTION SYSTEM.
DK3421471T3 (en)	2006-04-25	2021-06-14	Astex Therapeutics Ltd	PURIN AND DEAZAPURIN DERIVATIVES AS PHARMACEUTICAL COMPOUNDS
US20070260203A1 (en) *	2006-05-04	2007-11-08	Allergan, Inc.	Vasoactive agent intraocular implant
TW200808819A (en) *	2006-06-19	2008-02-16	Solvay Pharm Gmbh	Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
PL2201012T3 (en)	2007-10-11	2014-11-28	Astrazeneca Ab	Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
EP2247596A2 (en)	2008-01-11	2010-11-10	Natco Pharma Limited	Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
AR070127A1 (en)	2008-01-11	2010-03-17	Novartis Ag	PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
EA027506B1 (en)	2011-04-01	2017-08-31	Астразенека Аб	Method of treating breast cancer
HRP20191982T4 (en)	2011-11-30	2023-01-06	Astrazeneca Ab	Combination treatment of cancer
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
CN104350056A (en) *	2012-06-07	2015-02-11	霍夫曼-拉罗奇有限公司	Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
SI3010503T1 (en)	2013-06-21	2020-07-31	Zenith Epigenetics Ltd.	Novel bicyclic bromodomain inhibitors
JP6461118B2 (en) *	2013-06-21	2019-01-30	ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＬｔｄ．	Novel substituted bicyclic compounds as bromodomain inhibitors
JP6542212B2 (en)	2013-07-31	2019-07-10	ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＬｔｄ．	Novel quinazolinones as bromodomain inhibitors
US10710992B2 (en)	2014-12-01	2020-07-14	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en)	2014-12-01	2019-01-15	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Corp.	Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en)	2014-12-17	2016-06-23	Olesya KHARENKO	Inhibitors of bromodomains
EA036122B1 (en) *	2015-01-20	2020-09-30	Уси Форчун Фармасьютикал Ко., Лтд	Jak inhibitor
AU2016254385B2 (en)	2015-04-29	2018-05-10	Wuxi Fortune Pharmaceutical Co., Ltd	JAK inhibitors
KR102081272B1 (en)	2015-05-29	2020-02-25	우시 포춘 파마슈티컬 컴퍼니 리미티드	Janus kinase inhibitor
CN105771672B (en) *	2016-04-18	2018-03-02	天津工业大学	A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method
EP3594216B1 (en) *	2017-03-07	2022-04-06	Guangzhou Maxinovel Pharmaceuticals Co., Ltd.	Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
CN108017584B (en) *	2017-06-20	2021-03-23	南开大学	A3Small molecule antagonists of adenosine receptors
CA3100923A1 (en) *	2018-06-04	2019-12-12	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (en) *	2019-05-22	2021-08-31	北京大学深圳研究生院	The preparation method of 5-substituted β-proline and its derivatives
CN110272373B (en) *	2019-07-02	2022-07-29	天津国际生物医药联合研究院	Selective adenosine A 1 Receptor antagonists and uses thereof
CN114085178A (en) *	2021-12-29	2022-02-25	苏州楚凯药业有限公司	Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR19990067704A (en) *	1992-12-17	1999-08-25	디. 제이. 우드, 스피겔 알렌 제이	Pharmaceutical composition containing pyrrolopyrimidine as an adrenal cortical stimulating hormone free factor antagonist
US5780450A (en) *	1995-11-21	1998-07-14	Alcon Laboratories, Inc.	Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
JP4611524B2 (en) *	1998-06-02	2011-01-12	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	Pyrrolo [2,3d] pyrimidine compositions and uses thereof
HK1050319B (en) *	1999-12-02	2007-04-04	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
DK1450811T3 (en) *	2001-11-30	2010-02-15	Osi Pharm Inc	Compounds specific for adenosine A1 and A3 receptors and uses thereof

2001
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en not_active Ceased
- 2001-11-30 EA EA200300628A patent/EA007254B1/en not_active IP Right Cessation
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/en unknown
- 2001-11-30 IL IL15596201A patent/IL155962A0/en unknown
- 2001-11-30 PL PL01363245A patent/PL363245A1/en not_active Application Discontinuation
- 2001-11-30 YU YU42703A patent/YU42703A/en unknown
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/en active IP Right Grant
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/en unknown
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/en not_active Expired - Fee Related
- 2001-11-30 CN CNB018224601A patent/CN1263757C/en not_active Expired - Fee Related
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/en unknown
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/en not_active Application Discontinuation
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
MEP35308A (en)	2011-02-10
CN1263757C (en)	2006-07-12
OA13295A (en)	2007-04-13
EA200300628A1 (en)	2003-12-25
AP1893A (en)	2008-09-23
JP4579497B2 (en)	2010-11-10
NO20032482L (en)	2003-07-28
WO2002057267A1 (en)	2002-07-25
EA007254B1 (en)	2006-08-25
MXPA03004717A (en)	2004-06-30
AP2003002807A0 (en)	2003-06-30
HUP0400692A3 (en)	2007-09-28
EP1347980A4 (en)	2005-02-09
EP1347980A1 (en)	2003-10-01
JP2004517896A (en)	2004-06-17
CA2430577A1 (en)	2002-07-25
AU2002248151B2 (en)	2008-02-21
CN1489590A (en)	2004-04-14
NO20032482D0 (en)	2003-06-02
ZA200303729B (en)	2004-05-14
NO327207B1 (en)	2009-05-11
CZ20031831A3 (en)	2004-05-12
BR0115847A (en)	2004-02-25
YU42703A (en)	2006-03-03
IL155962A0 (en)	2003-12-23
HUP0400692A2 (en)	2004-07-28
NZ525885A (en)	2005-01-28

Legal Events

Date	Code	Title	Description
2011-09-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL363245A1 (en)	2004-11-15	Compounds specific to adenosine a1
GB0022370D0 (en)	2000-10-25	Improvements to televisionn system
EP1287154A4 (en)	2010-12-15	Charge-switch nucleotides
GB0006513D0 (en)	2000-05-10	Improvements relating to converters
GB0006247D0 (en)	2000-05-03	Improvements in or relating to organic compounds
GB0021404D0 (en)	2000-10-18	Improvement in or to organic compounds
GB2360322B (en)	2003-08-06	Improvements relating to fasteners
GB2364338B (en)	2004-01-28	Improvements relating to construction
GB0028814D0 (en)	2001-01-10	Improvements relating to biosorbtion
GB0025524D0 (en)	2000-11-29	Improvements relating to screenboxes
GB2363331B (en)	2003-02-05	Supplement to enhance fertility
GB0121137D0 (en)	2001-10-24	Improvements to motorbility vehicles
GB2388346B (en)	2004-01-21	Improvements relating to vehicles
GB0013038D0 (en)	2000-07-19	Improvements relating to bicycles
GB2359528B (en)	2004-01-21	Improvements relating to vehicles
GB0029842D0 (en)	2001-01-24	Improvements relating to thermometers
GB0017107D0 (en)	2000-08-30	Improvements to velodromes
GB0025715D0 (en)	2000-12-06	Improvements relating to haribrushes
HRPK20000423B1 (en)	2002-06-30	Novel nucleosides
GB0022811D0 (en)	2000-11-01	Improvements relating to supports
GB0007565D0 (en)	2000-05-17	Improvements relating to radiators
GB0029608D0 (en)	2001-01-17	Improvements relating to lamp-holder
GB9906671D0 (en)	1999-05-19	Improvements relating to forms
GB0008226D0 (en)	2000-05-24	Improvements relating to spanners
GB9903159D0 (en)	1999-04-07	Improvements relating to window-walls